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istal Myocardial Protection During
ercutaneous Coronary Intervention
hen and Where?
iana A. Gorog, MD, PHD, MRCP, Rodney A. Foale, MD, FRCP, Iqbal Malik, PHD, MRCP
ondon, United Kingdom
The discrepancy between angiographic success and microvascular perfusion has been
recognized for some time. In the face of an open artery, the degree of microvascular perfusion
determines post-infarct prognosis. Despite successful epicardial recanalization, tissue perfu-
sion may be absent in up to 25% patients with acute myocardial infarction. Historically
associated with saphenous vein graft intervention, embolization is increasingly recognized in
native coronary arteries, particularly in patients undergoing primary percutaneous coronary
intervention (PCI). With more than two million PCI procedures performed worldwide each
year, there is enormous interest in protecting the left ventricular myocardium from
embolization during PCI. This article reviews the evidence for distal myocardial protection
and discusses the relative merits of the different available techniques. (J Am Coll Cardiol
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.04.0612005;46:1434–45) © 2005 by the American College of Cardiology Foundation
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tistal protection devices (DPDs) were first introduced for
erebral protection during carotid artery stenting (CAS) (1).
n this setting, registries have demonstrated that use of
PDs may halve the combined end point of stroke or death
2,3).
Although angiographic evidence represents only the tip
f the embolization iceberg during percutaneous coronary
ntervention (PCI), even this occurs in up to 15% patients
ndergoing primary PCI (4). Angiographic indicators of
mbolization such as corrected Thrombolysis In Myocardial
nfarction (TIMI) frame count and myocardial blush grade
MBG), as well as rapidity of ST-segment resolution, are
ighly predictive of clinical and functional outcome (5,6).
That these phenomena are a manifestation of emboliza-
ion, rather than de novo thrombus formation, is borne out
y histological data showing, during elective PCI, emboli
omprised of mucopolysaccharide components and necrotic
ores (6–11). Vulnerable plaque morphology, namely dis-
uption or thinning of the fibrous cap, overlying thrombus,
nd increased lipid content are associated with complica-
ions from endovascular procedures (12,13). High plaque
acrophage content and plasma matrix metalloproteinase 9
MMP9) levels may predict embolization during PCI,
ossibly due to thinning of the fibrous cap by MMP9
ecreted by plaque macrophages (14). In addition to me-
hanical obstruction, the local response to embolization may
ontribute to myonecrosis (15–19).
It is thus not surprising that emboli are resistant to
ntiplatelet medication. Although use of glycoprotein (GP)
Ib/IIIa inhibitors has contributed to improved success rates
From the Waller Cardiac Department, St. Mary’s Hospital, London, United
ingdom.p
Manuscript received February 5, 2005; revised manuscript received April 12, 2005,
ccepted April 15, 2005.ith PCI, intervention in saphenous vein grafts (SVG) and
n native vessels with high intraluminal thrombus burden
ontinues to be hampered by thromboembolic events.
YPES OF DEVICES
vailable devices fall into four categories (Table 1):
istal filtration devices
istal occlusion devices
roximal occlusion devices
hrombus extraction devices
The devices with widest evidence base in each category
re the EZ-FilterWire (Boston Scientific, Natick, Massa-
husetts), the GuardWire (Medtronic AVE, Santa Rosa,
alifornia), Proxis (Velocimed, Maple Grove, Minnesota),
nd X-Sizer (EndiCOR Medical, San Clemente, Califor-
ia) systems, respectively. This review will therefore con-
entrate predominantly on these systems.
The FilterWire system (Fig. 1) incorporates a nonocclu-
ive filter (pore size 110 m) in the shape of a windsock,
ounted on a nitinol loop, and fixed on its own guidewire,
hich is deployed through a 3.2-F delivery sheath. The
itinol loop self-expands to fit vessels 3.5 to 5.5 mm in
iameter, and intervention performed over the wire. Finally,
he device is captured using a 4-F retrieval sheath. Other
ltration devices work similarly.
The GuardWire temporary occlusion-aspiration system
Fig. 2) consists of a guidewire incorporating a central
nflation lumen, to which an elastomeric balloon is attached.
his has a 2.8-F crossing profile, and injection of diluted
ontrast results in balloon inflation (2.5- to 5.0-mm or 3.0-
o 6.0-mm diameter), arresting anterograde flow. Interven-
ion is performed over the wire, and liberated debris trapped
roximal to the balloon aspirated through a 5-F monorail
E
a
d
c
(
t
p
d
a
r
s
n
t
s
b
u
t

m
U
T
a
t
T
t
T
E
-
-
-
-
S
-
-
-
-
A
-
-
C
R
-
-
-
-
I
-
-
1435JACC Vol. 46, No. 8, 2005 Gorog et al.
October 18, 2005:1434–45 Embolic Protection During PCIxport Aspiration catheter. The balloon is then deflated
nd flow restored.
The Proxis system incorporates a sealing balloon that is
eployed upstream of the stenosis to create a stagnant
able 1. Embolic Protection and Thrombectomy Devices Availab
Filter-Based Systems
Distal Occlusion-
Aspiration Systems
Z-FilterWire (EPI, Boston Scientific)
fixed to its own guidewire
3.2-F crossing profile
110 m pores
6-F guide-compatible
GuardWire (Medtronic)
-2.8-F crossing profile
-7-F guide-compatible
pider and Microvena Trap
(eV3, Minneapolis, Minnesota)
monorail system
Heprotec coating prevents thrombin
build-up
3.2- and 2.9-F crossing profiles
6F guide-compatible
TriActiv system (Kensey Nash
ngioguard (Cordis)
100 m pores
7-F guide-compatible
ardioshield and Neuroshield
(Mednova/Abbott, Galway, Ireland)
ubicon (Rubicon Medical Corp.)
100 m pores
fixed to its own guidewire
2-F crossing profile
6-F guide-compatible
nterceptor (Medtronic AVE)
100 m pores
6-F guide-compatible
Abbreviations and Acronyms
AMI  acute myocardial infarction
ACS  acute coronary syndromes
CAPTIVE  CardioShield Application Protects During
Transluminal Intervention of Vein Grafts
by Reducing Emboli
CAS  carotid artery stenting
DPD  distal protection device
GP  glycoprotein
MACE  major adverse cardiac event
MBG  myocardial blush grade
MMP9  matrix metalloproteinase 9
PCI  percutaneous coronary intervention
PRIDE  PRotection During Saphenous Vein Graft
Intervention to Prevent Distal
Embolization
SAFE  Saphenous Vein Graft Angioplasty Free of
Emboli trial
SAFER  Saphenous Vein Graft Angioplasty Free of
Emboli Randomized trial
SVG  saphenous vein graftolumn of blood in which intervention is performed
Fig. 3). Protection is thus in place before any device crosses
he lesion. The device is 7- or 8-F guide compatible, and
rotects vessels 2.5 to 5 mm in diameter. The stent is
elivered through the Proxis system, and flow is reversed,
spirating debris, before the sealing balloon is deflated,
estoring flow.
The X-Sizer system (Fig. 4) consists of a 1.5- or 2.0-mm
tainless steel helical cutter in a protective housing con-
ected to a 4.5- or 5.5-F dual-bore catheter shaft containing
he guidewire and vacuum/extraction lumens. The catheter
haft is linked to a handheld control module and vacuum
ottle in which debris is collected. Activating the control
nit simultaneously activates the helical cutter, which ex-
ends 1 mm beyond the protective housing, rotating at
2,100 rpm and initiates the vacuum, resulting in tissue
aceration, excision, and aspiration.
SE IN ACUTE CORONARY SYNDROMES (ACS)
able 2 shows the trials employing DPD in ACS (trial
cronyms explained in Table 3). There have been concerns
hat DPD use during primary PCI might delay reperfusion.
he first study using the FilterWire in primary PCI showed
hat successful DPD positioning was achieved in 89% of
in Development
Thrombectomy Devices
Proximal Balloon Occlusion-
Flow Reversal Systems
X-Sizer (Endicor)
-4.5- or 5.5-F crossing profile
-6- or 8-F guide-compatible
-compatible with any guidewire
Proxis (Velocimed)
-7/8-F guide-compatible
-compatible with
any guidewire
AngioJet (Possis) Kerberos Rinspirator/Protection
device (Kerberos)
Hydrolyzer (Cordis) Parodi Anti-embolization
device (ArteriA)
Rescue (Boston Scientific)
-4.5-F crossing profile
-7-F guide-compatible
MO.MA occlusion system
(Invatec, Brescia, Italy)
Pronto (Vascular Solutions)
-7-F guide-compatible
Diver (Invatec, Brescia, Italy)
-3.8-F crossing profilele or
)-6-F guide-compatible
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Embolic Protection During PCI October 18, 2005:1434–45atients in 10 min (6). Compared to historical controls,
ilterWire use improved final angiographic characteristics
nd left ventricular performance. Among the several limi-
ations of this study, final TIMI flow grade 3 in 85% of
atients in the control group may have lead to overestima-
ion of the benefit of the DPD.
A small study using the GuardWire in patients with
ngiographic “high-burden thrombus” undergoing primary
CI showed improved flow and MBG, but this did not
ranslate into a reduction in 30-day major adverse cardiac
vents (MACE) (20). The EMERALD study was the first
arge randomized trial to evaluate the GuardWire in pa-
ients with acute myocardial infarction (AMI). Although
he device markedly reduced the incidence of angiographic
low/no-reflow, there was no significant overall effect on
igure 1. The FilterWire system. (Panel 1) The polyurethane porous m
istal to the lesion, and the nitinol loop self-expands to fit the vessel upo
hrombus, seen as intraluminal filling defect (A), treated with percutaneous c
tenting (C).T-segment resolution or infarct size. Preliminary results mrom the first 188 patients undergoing PCI using the
uardWire in the RUBY registry have suggested that direct
evice delivery was possible in 87% cases, with favorable
ngiographic and electrocardiogram characteristics and low
linical event rates. In the PROMISE study, use of the
ilterWire-EX in patients undergoing primary PCI did not
mprove reperfusion and did not reduce infarct size com-
ared with usual care.
There are no data on the safety or efficacy of proximal
cclusion systems in AMI.
X-Sizer thrombectomy was first assessed in a small
andomized study of patients with suspected intracoronary
hrombus (21). Although the study failed to show a benefit
n final angiographic characteristics, creatine kinase-MB, or
0-day MACE, X-sizer pretreatment was associated with
rane filter attached to a nitinol loop. (Panel 2) The filter is deployed
action of the delivery sheath. (Panel 3) Saphenous vein graft containing
ry intervention using FilterWire protection (B), achieving a good result afteremb
n retr
oronaore rapid normalization of epicardial flow and, in patients
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October 18, 2005:1434–45 Embolic Protection During PCIith ST-segment elevation myocardial infarction, more
apid ST-segment resolution. The study was underpowered
o detect a benefit in clinical parameters. In AMI patients
ith angiographic evidence of thrombus (22), thrombec-
igure 2. The GuardWire system. Upper panel corresponds to lower panel
A), connected to the EZ Flator, which is inflated to occlude the vessel (B).
ein graft.
igure 3. The Proxis system is delivered through a guiding catheter, andt
he sealing balloon (A) is inflated proximal to the stenosis, arresting flow,
nd debris aspirated through the Proxis system (B).omy significantly improved pre-PCI flow, post-procedural
BG, and ST-segment resolution, but this was not re-
ected in hard clinical end points, and the device failed to
raverse the lesion in 9% of patients.
In the VeGAS-2 study, the AngioJet thrombectomy
evice (Possis, Minneapolis, Minnesota) was compared
ith intracoronary urokinase infusion (23). Although
hrombectomy was technically successful and reduced in-
ospital MACE, the results were clouded by subsequent
tudies demonstrating worse outcomes with urokinase than
ith placebo in patients with thrombotic lesions undergoing
CI (24). The disappointing results of the AIMI study,
resented at Transcatheter Cardiovascular Therapeutics
TCT) 2004, showed that AngioJet use paradoxically in-
reased infarct size.
There seem to be no data to suggest that routine use of
ny DPD system is beneficial in patients with ACS under-
oing PCI. However, it may be hard to show the benefit of
rotection against embolization that undoubtedly happens
uring angioplasty for AMI. In a prothrombotic milieu,
hrombi may form on the downstream (low pressure) side of
uardWire, used to cross the lesion, is inserted into the MicroSeal Adapter
is is aspirated using the Export Aspiration catheter (C). SVG saphenous: the Ghe protection device and embolize. Furthermore, fragmen-
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Embolic Protection During PCI October 18, 2005:1434–45ation of large thrombi by GP IIb/IIIa inhibitors or throm-
olysis may result in small particles that pass through the
lter. Lastly, in contrast to the cholesterol emboli released in
VG intervention, the consequence of embolization during
MI is not a fait accompli, because thrombotic platelet
mboli may subsequently be lysed in the distal myocardial
ed, without sequelae. Thus, the significance of emboliza-
ion during AMI may depend on the nature of the embolic
igure 4. The X-Sizer thrombectomy system comes ready to assemble in
ngiogram of right coronary artery proximally occluded by thrombus (A)
hrombectomy (C).aterial and integrity of endogenous thrombolytic response. tSE IN SVG
athophysiology. Saphenous vein graft interventions carry
20% risk of MACE, predominantly AMI, and significant
isk of no-reflow (25). The protection offered by GP
Ib/IIIa inhibitors during native vessel PCI has not been
irrored in SVG intervention (26,27), reflecting the differ-
ng composition of plaque in these settings; SVG plaques
(panel 1). Schematic of mechanism of action (panel 2). Panel 3 shows
zer thrombectomy device in situ (B), and angiographic appearance aftera tray
, X-siend to be cholesterol-rich, with relatively low calcium
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October 18, 2005:1434–45 Embolic Protection During PCIontent and less intimal proliferation than plaques in native
oronaries (28). Accordingly, debris embolized from SVG
argely consists of fibrin and necrotic core (29).
LINICAL STUDIES
he SAFE registry was the first to report on use of DPD in
VG intervention (Table 4) (29). Patients had relatively
ow-grade thrombus burden and good pre-procedural flow
TIMI flow grade 3, 84%). GuardWire balloon inflation
mean 5.4 min) was well-tolerated. Final angiographic
ppearances were excellent, and post-procedural creatine
inase-MB release compared favorably with historical con-
rols (30). These results spawned the larger SAFER trial,
hich confirmed the favorable effects on angiographic/
yonecrotic markers and clinical end points (31). Throm-
us burden was higher than in SAFE.
Use of the FilterWire was first reported in a registry
hich, like SAFE and SAFER, excluded patients with
MI or severe left ventricular failure (32). Pre-procedure
IMI flow grade 3 was present in 85% cases, with a
igher thrombus burden (65%) than in the GuardWire
rials. Analysis of phase I results identified several correct-
ble factors that led to improved results in phase 2 (see
echnical concerns in the following text). The trial high-
ighted the difficulty in predicting embolic risk during SVG
ntervention and the need for DPD deployment from the
utset of intervention.
A comparison of the GuardWire and FilterWire (FIRE)
n patients with low thrombus burden and good pre-
rocedural flow revealed similar rates of successful device
eployment, angiographic and myonecrotic end points, and
0-day MACE (33). Subgroup analysis suggested an ad-
antage of the FilterWire over the GuardWire in smaller
essels and eccentric lesions.
In an early safety and feasibility study in 40 patients
ndergoing mainly SVG PCI (FASTER) (34), the Proxis
ystem was successfully deployed in 95% of cases and
ppeared safe (MACE 5%). The first clinical trial with this
evice (PROXIMAL) is now under way (Table 5).
In the X-TRACT trial (35), use of the X-Sizer system
70% SVG) was not associated with reductions in MACE.
lthough the overall incidence of procedural AMI was
nchanged, the incidence of large infarcts was significantly
educed in the X-Sizer arm.
The results of two noninferiority studies, PRIDE (Tri-
ctiv, Kensey Nash, Exton, Pennsylvania) and CAPTIVE
CardioShield, MedNova, Galway, Ireland), using new
PD in SVGs were presented at TCT 2004. The TriActiv
ystem has three components: a distal protection balloon, a
-F flushing catheter, and a peristaltic pump extraction
ystem, which allow constant flushing and aspiration of
ebris. The PRIDE trial demonstrated noninferiority to
stablished DPD with respect to 30-day MACE. The
APTIVE trial, which assessed the CardioShield filter levice, failed to demonstrate both superiority to no embolic
rotection, and noninferiority to the GuardWire.
ECHNICAL CONCERNS
ailure to cross the lesion. The relatively large crossing
rofile and lack of torquability may make it technically
hallenging to advance these devices beyond a tight stenosis
r in a tortuous vessel. Some devices come loaded on their
wn delivery wire, the handling characteristics of which will
learly be better suited to crossing some vessels than others.
re-dilatation can overcome this problem, at the risk of
istal embolization before protection is in place. The im-
ortance of such early embolization should not be underes-
imated; significant embolization has been documented in
x vivo studies (36), and in patients undergoing CAS with
ranscranial Doppler monitoring (37,38).
ositioning. In AMI with TIMI flow grade 0, it may be
ifficult to know where to position the DPD, in order to be
ar enough away from the lesion to allow unimpeded
tenting, yet in a part of the artery large enough to
ccommodate the device, and proximal to major side
ranches.
izing the device. Some devices, such as the FilterWire,
xpand to fit a range of vessel diameters. However, with
ther systems, the size of the distal vessel may be underes-
imated if flow is reduced, and device malapposition due to
ndersizing may allow distal embolization.
ide-branch protection. In Y anastomotic grafts or distal
raft lesions where the native vessel run-off gives off early
ajor side-branches, it may be difficult to position the DPD
uch that side-branches are protected. To overcome this,
wo similar devices may be used in each branch (“kissing”
lters), assuming that the caliber of both branches is
ommensurate with use of a DPD. Alternatively, a filter-
ype device may be deployed in one branch and an
cclusion-aspiration or thrombectomy device used in the
ther. Importantly, these techniques will be feasible for
alloon angioplasty but may make stenting challenging, in
rder to avoid jailing the wires of either DPD during stent
eployment.
ersistent embolization. Using balloon occlusion systems,
mbolization may occur due to gradual balloon deflation
uring the procedure. Minor deflation may be difficult to
etect without frequent injections of contrast to ensure a
ight seal, but this itself may cause embolization with an
nadequate seal. Furthermore, debris may fail to be aspirated
y the suction catheter, either because of resistance to
spiration or because the catheter cannot approach suffi-
iently close, leaving a “suction shadow” of embolic material
ehind (39). With filter-based devices, incomplete apposi-
ion is a significant concern and has been found to correlate
ith periprocedural AMI (32). This may be easily missed
ithout orthogonal views to assess the filter both en face
nd in profile. The most common cause of malapposition is
ifting of the nitinol frame away from one side of the vessel
Table 2. Trials Employing Embolic Protection in ACS
Trial
Name Clinical Syndrome Device
No. of
Patients Management Strategy Other Agents Used End Point
Results
(Intervention vs. Control)
Limbruno
et al. (6)
Primary PCI FilterWire 53 Registry; matched historical
controls
Success of DPD delivery
Post-procedure cTFC
Post-procedure MBG 3
ST-segment resolution
Peak CKMB
30-day LVEF
89%
22 vs. 31, p  0.005
63 vs. 36, p  0.006
80% vs. 54%, p  0.006
236 vs. 333, p  0.01
7% vs. 4%, p  0.012
Orrego et al.
Cath
Cardiovasc
Int 2003
Primary PCI FilterWire vs.
GuardWire
10
23
Non randomized, first 22
consecutive patients treated
with GuardWire, next 10
with FilterWire
Abciximab Success of DPD delivery
Final TIMI flow grade 3
ST-segment score
Distal embolization
86% vs. 90%
(GuardWire vs. FilterWire)
84% vs. 89%
(GuardWire vs. FilterWire)
4.7 vs. 5.1
(GuardWire vs. FilterWire)
10% vs. 22%
(GuardWire vs. FilterWire)
Yip et al. (20) Primary PCI (high
thrombus burden)
GuardWire 108 Registry; matched historical
controls treated with PCI
with tirofiban, without
GuardWire
Tirofiban Final TIMI flow grade 3
Final MBG
30-day MACE
95% vs. 75%, p  NS
2.4 vs. 1.6, p  NS
4.7% vs. 16.5%, p  0.006
EMERALD AMI, primary or rescue
PCI
GuardWire 500 Prospective, randomized trial,
GuardWire vs. no DPD
GP IIb/IIIa inhibitors in
83%
(1°) ST-segment resolution
(1°) Infarct size on sestamibi
(2°) TIMI flow grade 3
p  NS
p  NS
89% vs. 96% p  NS
RUBY ACS, predominantly
STEMI
GuardWire 328 total; results
of first 188
available
Prospective registry GP IIb/IIIa inhibitors in
35%
(1°) 30-day MACE
(2°) TIMI flow grade 3
(2°) Normal MBG
(2°) ST-segment resolution
2.7%
96%
50%
42%
PROMISE AMI (primary PCI) FilterWire 200 Prospective, randomized trial Abciximab (1°) Max flow velocity in IRA
(2°) Infarct size (% LV mass on
MRI)
p  NS
p  NS
Beran et al. (21) ACS, predominantly
STEMI
X-Sizer 66 Prospective, randomized trial,
X-Sizer vs. no
thrombectomy
GP IIb/IIIa inhibitors in
70% of both study
arms
TIMI flow grade 3
cTFC
ST-segment resolution
30-day MACE
Peak CKMB
90% vs. 84%, p  NS
18% vs. 25%, p  0.03
83% vs. 52%, p  NS
6% vs. 6%, p  NS
142 vs. 171, p  NS
Napodano
et al. (22)
AMI with angiographic
thrombus
X-Sizer 92 Prospective randomized trial,
randomized to X-Sizer vs.
no thromectomy
GP IIb/IIIa inhibitors in
43% of both study
arms
30-day MACE
30-day LVEF
Peak CKMB
Post-procedure TIMI flow
grade 3
Post-procedure MBG3
ST-segment resolution
11% vs. 11%, p  NS
52% vs. 50%, p  NS
182% vs. 229%, p  NS
94% vs. 96%, p  NS
72% vs. 37%, p  0.006
83% vs. 52%, p  0.001
TOPIT Thrombus-rich vessels TEC 251 Prospective randomized trial,
randomized to TEC vs. no
thrombectomy pre-PCI
In-hospital MACE 2.7% vs. 8.2%, p  NS
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October 18, 2005:1434–45 Embolic Protection During PCIall due to wire bias (32), and may be corrected by
epositioning the filter.
The benefit of filter devices over balloon occlusion sys-
ems is the preservation of flow. This is a two-edged sword
ecause it also allows the passage of smaller microemboli.
he SAFE registry revealed that 80% of particles collected
ere smaller than 100 m diameter, although it is impos-
ible to know how much suction/aspiration contributed to
article break up (29).
Embolization may also occur during device retrieval.
ilters may become full, and may spill their contents when
ollapsed during retrieval. Newer devices will incorporate a
uilt-in shutter mechanism to close the mouth of the filter
efore retrieval.
etrieval. The relatively large-profile aspiration catheter or
he retrieval catheter of the filter devices may become caught
n stent struts.
se in small vessels. Use of either DPD or thrombectomy
s generally recommended for vessels 3.0 to 3.5 mm in
iameter. Recently, the first small study employing the
able 3. Summary of Trial Acronyms
AIMI  AngioJet Rheolytic Thrombectomy in Patients Undergoing
Primary Angioplasty for AMI
AMEthyst  Assessment of the Medtronic AVE Interceptor Saphenous
Vein Graft Filter System
CAPTIVE  Cardio-Shield Application Protects During Transluminal
Intervention of Vein Grafts by Reducing Emboli
DEAR-MI  Dethrombosis to Enhance Acute Reperfusion in
Myocardial Infarction
EMERALD  Enhanced Myocardial Efficacy and Recovery by
Aspiration of Liberalized Debris
FASTER  Evaluation of the Proxis embolic protection system during
stenting of coronary arteries and degenerated saphenous vein grafts
FIRE  FilterWire EX During Transluminal Intervention of
Saphenous Vein Grafts
GUARD  SVG Intervention Using AngioGuard for reduction of
Distal Embolization
PRIDE  PRotection During Saphenous Vein Graft Intervention to
Prevent Distal Embolization
PROMISE  Protection Devices in PCI-Treatment of Myocardial
Infarction for Salvage of Endangered Myocardium Study
PROXIMAL  PROXimal Protection During Saphenous Vein Graft
Intervention Using the Proxis Embolic Protection System: A
Randomized, Prospective, Multicenter TriAL
RUBY  Revascularization Utilizing Balloon protection in Acute
CoronarY Ischemic Syndrome
RULE SVG  RUbicon FiLtEr SVG
SAFE  Saphenous Vein Graft Angioplasty Free of Emboli trial
SAFER  Saphenous Vein Graft Angioplasty Free of Emboli
Randomized trial
SAPPHIRE  Stenting and Angioplasty with Protection in Patients at
High Risk for Endarterectomy
SPIDER  Evaluation of the Spider embolic protection system during
stent treatment of degenerated saphenous vein grafts
TOPIT  TEC or PTCA in Thrombus
VeGAS-2  Vein Graft AngioJet Study 2
X-TRACT  Prospective, randomized evaluation of thrombectomy
prior to PCI in diseased SVGs and thrombus-containing coronary
arteries
or further information, refer to: http://www.tctmd.com.FilterWire in small native vessels (2.6  0.5 mm diameter)Ta
b
V
eg
A
IM
A
C
S
ca
rd
gr
af
Table 4. Trials Using Embolic Protection in SVG Intervention
Trial
Name
Clinical
Syndrome Device
No. of
Patients
Management
Strategy
Other Agents
Used End Point
Results
(Intervention vs. Control)
SAFE Elective SVG intervention
(low thrombus burden)
GuardWire 105 Registry (1°) In-hospital MACE
(2°) Final TIMI grade 3
flow
(2°) No reflow
(2°) CKMB 3 ULN
5%
99%
0%
5%
SAFER Elective SVG intervention
(moderate thrombus
burden)
GuardWire 801 Randomized to GuardWire
vs. no DPD
GP IIb/IIIa inhibitor
in 58% lesions in
both arms
30-day MACE
No reflow
3% vs. 9%, p  0.02
9.6% vs. 16.5%, p  0.004
Stone et al.
(32)
Elective SVG intervention
(High thrombus burden)
FilterWire 60 (phase 1)
248 (phase 2)
Registry GP IIb/IIIa inhibitor
in 30% lesions
(phase 1), in 52%
lesions (phase 2)
30-day MACE 21% (phase 1)
11% (phase 2)
FIRE Elective SVG intervention
(Low thrombus burden)
FilterWire vs. GuardWire 651 Prospective randomized trial GP IIb/IIIa inhibitor
in 52% lesions in
both arms
(1°) 30-day MACE successfull
DPD delivery
Angiographic and
myonecrotic end points
10% vs. 12% (FilterWire vs.
GuardWire)
p  NS for superiority
p  0.008 for inferiority
X-TRACT SVG (70%) or thrombus-
rich native vessel (30%)
X-Sizer vs. no DPD 50 (phase 1)
797 (phase 2)
Prospective randomized trial GP IIb/IIIa inhibitor
in 76% lesions in
both arms
30-day MACE
1-year MACE
Periprocedural AMI (any)
Large AMI (CKMB 8
ULN)
17% vs. 17%, p  NS
31% vs. 28%, p  NS
16% vs. 17%, p  NS
5% vs. 10%, p  0.002
PRIDE SVG TriActive vs.
FilterWire/GuardWire
631 Prospective randomization to
TriActive system vs.
established DPD
(FilterWire or
GuardWire)
Uncertain, pending
full trial
publication
30-day MACE 11% vs. 10%, p  NS
CAPTIVE SVG CardioShield vs.
GuardWire
652 Prospective randomization to
CardioShield vs.
GuardWire
Uncertain, pending
full trial
publication
30-day MACE 10% vs. 12%, p  NS
ULN  upper limits of normal; other abbreviations as in Tables 1 and 2.
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October 18, 2005:1434–45 Embolic Protection During PCIith moderate-complex lesions has revealed high rates of
rocedural success, no device-related vessel dissection, and
istal embolization in only 4% patients (40). Although
asospasm (50%) and reduction in coronary flow (45%) were
requent, these universally resolved after device retrieval.
se in large vessels. Degenerative SVGs can become
arkedly ectatic, and the risk of no reflow during PCI is
articularly high. Although DPD do not generally expand
o 6 mm in diameter, a larger range of devices is expected
o become available soon.
ncertain clinical scenarios. Almost all available clinical
ata are in men, with very limited data in diabetics. There
re no data on the tolerability of the balloon occlusion
ystems in patients with poor left ventricular function or
MI and cardiogenic shock. Studies are needed to deter-
ine whether combined treatment with both thrombec-
omy and DPD will confer additional advantages. Whether
se of GP IIb/IIIa inhibitors or lytic therapy combined with
PD will offer additional benefit, or whether it reduces the
ize of embolizing particles such that these pass through
lters unhindered, remains to be determined. In the X-Sizer
MI registry, where 43% of patients received abciximab
22), no difference in TIMI flow grade 3 or MBG was
ound according to abciximab use.
ILTER, BALLOON-OCCLUSION,
ND ASPIRATION, OR THROMBECTOMY?
n deciding on the best protection strategy, it is important to
onsider specific lesion and vessel characteristics, as well as
hrombus burden. Electron microscopy of material aspirated
ith the GuardWire system showed particles ranging from
.6 to 5,262 m in diameter, 50% of which were 100 m
29,41). Filter devices have 80- to 150-m pores, and may
able 5. Ongoing Trials Using Embolic Protection in Coronary
Trial Name
Clinical
Syndrome
Type of
Investigational
Device Device P
ROXIMAL SVG intervention PPD Proxis
EAR-MI AMI Thrombectomy Pronto
ULE-SVG PCI to SVG Filter Rubicon
PIDER PCI to SVG Filter SpideRX
UARD PCI to SVG Filter AngioGuard
MEthyst PCI to SVG Filter Interceptor
PD  proximal protection device; other abbreviations as in Tables 1 and 2.herefore allow significantly more debris to pass through. nlthough smaller pore sizes might appear advantageous,
hese also cause more frequent filter thrombosis (42) with a
ize of 100 m representing a reasonable compromise.
hy then do filters with 100-m pores appear to offer equal
enefit to balloon occlusion systems when half the particles
re under that size? Although it is possible that the cardiac
nd points examined thus far have been too crude to assess
he effects of “trashing” by smaller microemboli, it is equally
ossible that, unlike the brain, a shower of smaller emboli
hat is not reflected in a troponin rise or decline in left
entricular function is of no clinical significance.
The important benefit of filter devices over occlusion
alloon systems is flow preservation. The occlusion-
spiration systems require a period of balloon inflation of
everal minutes. There may be situations in which this is
nacceptable, for example when a large volume of uncollat-
ralized myocardium is subtended by the target vessel, or in
ases of severe left ventricular dysfunction, where even a
rief period of ischemia may be poorly tolerated. In these
nstances, filter-based protection would intuitively seem
referable. Generally, the left anterior descending coronary
rtery and the right coronary artery lend themselves well to
PDs, whereas the anatomy of the circumflex is less
ccommodating. The X-Sizer lends itself best to SVG and
ight coronary artery lesions, with a relatively straight “run.”
lthough the benefit of thrombectomy on clinical end
oints is unproven, there may be a niche for such devices in
linical situations where DPDs cannot be used, such as in
ery distal SVGs and bifurcation points, or where thrombus
urden is overwhelming for filter protection.
EWER DEVICES
able 1 lists some of the newer devices, many of which are
vention
f
ts Management Strategy Primary End Point Results
Randomized to Proxis or
other (FDA approved)
DPD
30-day MACE Ongoing
Randomized to Pronto
thrombectomy vs. no
treatment prior-to
primary PCI
-Myocardial reperfusion
(ST-segment resolution)
-Echocardiographic
recovery of LV
function
Ongoing
Randomized to Rubicon
vs. no protection
30-day MACE Ongoing
Randomized to SpideRX
or GuardWire
30-day MACE Ongoing
Randomized to
AngioGuard or
GuardWire
(Protocol not published) Ongoing
Randomized to
Interceptor or
GuardWire
30-day MACE OngoingInter
No. o
atien
600
200
60
770
800
600ot yet commercially available. Table 5 shows some of the
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Embolic Protection During PCI October 18, 2005:1434–45ngoing clinical trials. Filters include the Spider and TRAP
ardiovascular filtration systems, the AngioGuard, and the
nterceptor (Medtronic AVE). The coaxial actuating wire
esign of the Rubicon wire (Rubicon Medical Corp., Salt
ake City, Utah) eliminates the need for a delivery catheter,
llowing a stent to be preloaded onto the wire, and both
evices delivered in one step.
The Parodi Anti-Embolic (ArteriA, San Francisco, Cal-
fornia) and the MO.MA systems consist of a guiding
atheter through which an elastomeric balloon is inflated
roximal to the stenosis in the common carotid, and a
econd balloon inflated in the external carotid, causing
etrograde flow in the internal carotid artery during inter-
ention. Experience with both systems remains confined to
AS due to the requirement for 10- to 11-F sheaths.
Hydrodynamic thrombectomy systems employ saline jets
manating from the catheter to create a vacuum via the
enturi effect and fragment the thrombus, which is sucked
nto the catheter. These include the AngioJet, the Hydro-
yser (Cordis, Miami, Florida), and the Kerberos Rinspirato
Kerberos, Cupertino, California). The Pronto (Vascular
olutions, Minneapolis, Minnesota) and the Rescue (Bos-
on Scientific) catheters use vacuum aspiration.
ONCLUSIONS
he efficacy of DPDs should be balanced against high
nitial costs, the risk of device-related vessel dissection,
ncreased procedural time, and the learning curve associated
ith their use.
In SVG intervention, both balloon occlusion/aspiration
nd filter-based DPDs have reduced the incidence of AMI
nd should remain the treatment of choice. In contrast, the
enefit of the X-Sizer device remains unproven and should
nly be considered where DPD cannot be used.
The jury is out regarding the usefulness of DPDs in ACS.
lthough histological studies have shown that filters con-
ain embolic debris in virtually all cases (6) and angiographic
esults are improved, this benefit has not been reflected in
educed infarct volume or hard clinical end points.
Finally, with increasing intervention in thrombus-rich
ilieux, as occurs during primary PCI, further studies are
eeded to establish the usefulness of DPDs in combination
ith GPIIb/IIIa inhibitors, with direct thrombin inhibitors,
nd in patients at highest risk, such as those with multivessel
isease or significant left ventricular impairment, who are
ikely to benefit most.
eprint requests and correspondence: Dr. Diana A. Gorog,
aller Cardiac Department, St. Mary’s Hospital, Praed Street,
ondon W2 1NY, United Kingdom. E-mail: dgorog@aol.com.
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